TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21324965

Group type: EXPERIMENTAL
Intervention: Patient Global Assessment (PGA) using a 0-100 mm visual analog scale (VAS)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Patient Joint Assessment (PJA) using a 0-100 mm VAS
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Patient Skin Assessment (PSA) using a 0-100 mm VAS
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: PGA scores
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: PJA scores
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: PSA scores
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Correlation between joint and skin disease activity
Number of subjects: 319
Study: 19363239

Group type: EXPERIMENTAL
Intervention: Haemorheopheresis (separator Cobe.Spetra + Evaflux filter)
Number of subjects: 24
Study: 17531926

Group type: EXPERIMENTAL
Intervention: Elevated BP group
Number of subjects: 66
Study: 15690714

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori eradication therapy; specific dosage and duration not mentioned.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo); specific details not mentioned.
Number of subjects: 0
Study: 11684821

Group type: EXPERIMENTAL
Intervention: Anti-tissue transglutaminase (tTG) test
Number of subjects: 258

Group type: COMPARATOR
Intervention: Control group of 180 healthy donors without hypertransaminasemia
Number of subjects: 258

Group type: COMPARATOR
Intervention: Control group of 20 CD patients known to be EmA positive
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Biopsy of distal duodenal mucosa
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Gluten-free diet
Number of subjects: 258
Study: 10518866

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate dentifrices (45% NaHCO3)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate dentifrices (65% NaHCO3)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate dentifrices (94% NaHCO3)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate dentifrices (94% NaHCO3 + 1.5% H2O2)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (distilled water)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Silica dentifrice (Crest Regular Toothpaste)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Dicalcium phosphate dentifrice (Colgate Regular Toothpaste)
Number of subjects: 12
Study: 8083147

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 5 mg, 10 mg, 15 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 2792618

Group type: EXPERIMENTAL
Intervention: Experimental group (n = 50) - received detailed information and extensive physical examination
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (n = 50) - received standard care
Number of subjects: 100
Study: 956343

Group type: EXPERIMENTAL
Intervention: Meclastine (oral administration for three days)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dexchlorpheniramine (intravenous infusion)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Insulin hypoglycemia
Number of subjects: 30
Study: 31612597

Group type: EXPERIMENTAL
Intervention: Acotiamide
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30655639

Group type: EXPERIMENTAL
Intervention: Therapeutic and dietetic intervention to correct hypotension until SBP > 100 mmHg
Number of subjects: 54
Study: 28522450

Group type: EXPERIMENTAL
Intervention: SGLT-2i
Number of subjects: 309056

Group type: COMPARATOR
Intervention: Other glucose-lowering drugs
Number of subjects: 309056
Study: 25614164

Group type: EXPERIMENTAL
Intervention: Riociguat, individually adjusted up to a maximum dose of 2.5 mg three times daily
Number of subjects: 396
Study: 24287218

Group type: EXPERIMENTAL
Intervention: Arm stretch positioning combined with motor amplitude NMES for two 45‐minute sessions a day, five days a week, for eight weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sham arm positioning and sham NMES (transcutaneous electrical nerve stimulation with no motor effect) to the forearm only, at a similar frequency and duration
Number of subjects: 46
Study: 21142844

Group type: EXPERIMENTAL
Intervention: Nucleoside and protease inhibitor antiretroviral therapy (ARV) during first trimester
Number of subjects: 1414

Group type: EXPERIMENTAL
Intervention: Nucleoside and protease inhibitor antiretroviral therapy (ARV) after first trimester
Number of subjects: 1414

Group type: EXPERIMENTAL
Intervention: Nucleoside and protease inhibitor antiretroviral therapy (ARV)
Number of subjects: 1414
Study: 18955451

Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg daily
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Imatinib 800 mg daily
Number of subjects: 428

Group type: COMPARATOR
Intervention: KIT exon 9-mutant genotype
Number of subjects: 428

Group type: COMPARATOR
Intervention: Wild-type (WT) genotype
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: CD117-negative GIST
Number of subjects: 428
Study: 16606651

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Etanercept and sulfasalazine
Number of subjects: 254

Group type: COMPARATOR
Intervention: Sulfasalazine
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Etanercept alone
Number of subjects: 254
Study: 15062131

Group type: EXPERIMENTAL
Intervention: 125I episcleral plaque radiotherapy (EPRT) with median dose of 80.0 Gy
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Episcleral hyperthermia (HT) with median temperature of 44 degrees C
Number of subjects: 35

Group type: COMPARATOR
Intervention: 125I episcleral plaque radiotherapy (EPRT) with median dose of 60.8 Gy
Number of subjects: 35
Study: 10824374

Group type: EXPERIMENTAL
Intervention: Videoconferencing assessment
Number of subjects: 23

Group type: COMPARATOR
Intervention: Face to face (FTF) assessment
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Telepsychiatry system
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Videoconferencing system
Number of subjects: 23
Study: 8856682

Group type: EXPERIMENTAL
Intervention: Simultaneous presence of the first tone (sustained neural activity)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preceding tone (control condition)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both conditions (sustained vs persisting neural activity)
Number of subjects: 0
Study: 6371152

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (20 micrograms per dose)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 30724660

Group type: EXPERIMENTAL
Intervention: CYD-TDV
Number of subjects: 1378
Study: 28835254

Group type: EXPERIMENTAL
Intervention: Routinely recorded clinical and non-clinical data access
Number of subjects: 98
Study: 25912588

Group type: EXPERIMENTAL
Intervention: valsartan (80 mg/d) and atorvastatin (20 mg/d)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: benazepril (10 mg/d) and atorvastatin (20 mg/d)
Number of subjects: 200
Study: 24590419

Group type: EXPERIMENTAL
Intervention: Dissonance intervention (MS Body Project)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Educational brochure control
Number of subjects: 133
Study: 23015654

Group type: COMPARATOR
Intervention: IGF‐I serum levels in men (137 ± 69 ng/ml for AD)
Number of subjects: 694

Group type: COMPARATOR
Intervention: IGFBP‐3 serum levels in men (3675 ± 1542 ng/ml for AD)
Number of subjects: 694

Group type: COMPARATOR
Intervention: IGFBP‐3 serum levels in women (3781 ± 1351 ng/ml for AD)
Number of subjects: 694

Group type: EXPERIMENTAL
Intervention: IGF‐I odds ratio in men
Number of subjects: 694

Group type: EXPERIMENTAL
Intervention: IGFBP‐3 odds ratio in men
Number of subjects: 694
Study: 19562320

Group type: EXPERIMENTAL
Intervention: Reniale (autologous tumour cell lysate vaccination therapy)
Number of subjects: 990

Group type: COMPARATOR
Intervention: Control (no adjuvant treatment)
Number of subjects: 990

Group type: EXPERIMENTAL
Intervention: Reniale (for patients with pT3 RCC)
Number of subjects: 990

Group type: COMPARATOR
Intervention: Control (for patients with pT3 RCC)
Number of subjects: 990

Group type: COMPARATOR
Intervention: Control (median survival for patients with pT3 RCC)
Number of subjects: 990

Group type: EXPERIMENTAL
Intervention: Reniale (Cox analysis)
Number of subjects: 990

Group type: EXPERIMENTAL
Intervention: Reniale (Cox analysis for pT3 tumours)
Number of subjects: 990
Study: 17898346

Group type: EXPERIMENTAL
Intervention: Olanzapine (2.5-20 mg/day)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study: 15824468

Group type: EXPERIMENTAL
Intervention: PACE+ Japan follow-up group (n=18)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (n=19)
Number of subjects: 57
Study: 11523669

Group type: EXPERIMENTAL
Intervention: Hypervolemic hypertensive hemodilution fluid therapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Normovolemic fluid therapy
Number of subjects: 32
Study: 9629947

Group type: EXPERIMENTAL
Intervention: BPI
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: BPII
Number of subjects: 42
Study: 7938758

Group type: EXPERIMENTAL
Intervention: Hemodialysis patients
Number of subjects: 151

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 151
Study: 3284630

Group type: EXPERIMENTAL
Intervention: Desipramine (150 mg/day) for six weeks
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo for six weeks
Number of subjects: 47
Study: 31313886

Group type: EXPERIMENTAL
Intervention: Bifocal glasses
Number of subjects: 119

Group type: COMPARATOR
Intervention: Unifocal glasses
Number of subjects: 119
Study: 29174273

Group type: EXPERIMENTAL
Intervention: Processed, encapsulated placenta (n=12)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (n=15)
Number of subjects: 27
Study: 29489108

Group type: EXPERIMENTAL
Intervention: Support ventilation modes during anesthesia
Number of subjects: 0
Study: 24258498

Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 34
Study: 24028542

Group type: EXPERIMENTAL
Intervention: Screening doors and windows with metal mesh and closing openings on eves and walls by mud
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study: 20428621

Group type: EXPERIMENTAL
Intervention: Incentive spirometry (IS) with expiratory positive airway pressure (EPAP)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study: 17692728

Group type: EXPERIMENTAL
Intervention: Suspension formulation of acyclovir 400 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Tablet formulation of acyclovir 400 mg
Number of subjects: 50
Study: 14757326

Group type: EXPERIMENTAL
Intervention: CRH(1)-receptor-antagonist R121919 (higher doses)
Number of subjects: 27

Group type: COMPARATOR
Intervention: CRH(1)-receptor-antagonist R121919 (lower doses)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: CRH(1)-receptor-antagonist R121919
Number of subjects: 27
Study: 11288847

Group type: EXPERIMENTAL
Intervention: Automatic bolus tracking (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Time delay (n = 20)
Number of subjects: 40
Study: 9709744

Group type: EXPERIMENTAL
Intervention: Laser treatment (standard intensity)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Laser treatment (less than standard intensity)
Number of subjects: 18
Study: 7995861

Group type: EXPERIMENTAL
Intervention: High fat feeding
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard isocaloric feeding
Number of subjects: 32
Study: 3135010

Group type: EXPERIMENTAL
Intervention: Bendrofluazide
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Propranolol (in non-smoking men)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Propranolol (in smokers)
Number of subjects: 100

Group type: COMPARATOR
Intervention: General treatment for women
Number of subjects: 100
Study: 29407665

Group type: EXPERIMENTAL
Intervention: Brief intervention in driving schools
Number of subjects: 1866

Group type: EXPERIMENTAL
Intervention: 5-HTTLPR genotype (S'-allele carriers)
Number of subjects: 1866

Group type: EXPERIMENTAL
Intervention: L'/L' homozygotes
Number of subjects: 1866
Study: 26754071

Group type: EXPERIMENTAL
Intervention: FENIX magnetic sphincter augmentation (MSA)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Sacral nerve stimulation (SNS)
Number of subjects: 350
Study: 25635887

Group type: EXPERIMENTAL
Intervention: Recombinant tissue‐type plasminogen activator
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study: 23725681

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 19878097

Group type: EXPERIMENTAL
Intervention: Hypertonic saline/hydroxyethyl starch (HSH)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Ringer's solution (CT group)
Number of subjects: 49
Study: 18379239

Group type: EXPERIMENTAL
Intervention: Documentation of a living will
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Absence of cardiopulmonary resuscitation performed in the last hour of life
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Withdrawal of tube feeding
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Family presence at time of death
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Discussion of the patient's wish to withdraw life support during a family conference
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Use of standardized comfort care orders
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Occurrence of a family conference
Number of subjects: 356
Study: 16677742

Group type: EXPERIMENTAL
Intervention: Camel's milk
Number of subjects: 8

Group type: COMPARATOR
Intervention: Cow's milk
Number of subjects: 8
Study: 15130632

Group type: EXPERIMENTAL
Intervention: CeeOn Edge 911A
Number of subjects: 288

Group type: COMPARATOR
Intervention: AcrySof MA60BM
Number of subjects: 288

Group type: COMPARATOR
Intervention: PhacoFlex SI-40NB
Number of subjects: 288
Study: 11486922

Group type: EXPERIMENTAL
Intervention: Curvilinear source-identification ROCs across various encoding and test conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Source-monitoring framework
Number of subjects: 0
Study: 9609409

Group type: EXPERIMENTAL
Intervention: 400 mg ibuprofen intravenously (i.v.)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 7924774

Group type: EXPERIMENTAL
Intervention: Low-birth-weight infants (<2.5 kg)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Infants small for gestational age
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Infants with corrected birth weight: length ratio below the 10th percentile
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Infants with corrected 6-month weight below the 10th percentile
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Exclusively breast-fed infants for 6 months
Number of subjects: 232
Study: 3071597

Group type: EXPERIMENTAL
Intervention: SMS 201-995
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 30676200

Group type: EXPERIMENTAL
Intervention: Alcohol administration (infusion resulting in an arterial blood alcohol concentration of 80 mg%)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo condition (saline infusion)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Alcohol administration
Number of subjects: 54
Study: 28650788

Group type: EXPERIMENTAL
Intervention: EndoVac system
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Conventional needle irrigation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2.5% sodium hypochlorite (NaOCl) + ethylenediaminetetraacetic acid (EDTA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ozonated water (OW) + EDTA
Number of subjects: 60

Group type: COMPARATOR
Intervention: 5.25% NaOCl
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 60
Study: 25873213

Group type: EXPERIMENTAL
Intervention: Bevacizumab (standard dose, monthly review)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Bevacizumab (low dose, monthly review)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Bevacizumab (standard dose, two-monthly review)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Bevacizumab (low dose, two-monthly review)
Number of subjects: 1000
Study: 23001556

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 30 mg, increased to 70 mg over 4 weeks and maintained for another 4 weeks
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Lisdexamfetamine dimesylate (LDX) and Placebo
Number of subjects: 63
Study: 21425570

Group type: EXPERIMENTAL
Intervention: Integrative medical therapy (Chinese drugs)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (basic therapy only)
Number of subjects: 36
Study: 19178385

Group type: EXPERIMENTAL
Intervention: Endurance exercise (thrice weekly 45‐min intervals)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control treatment (three 45‐min episodes of stretching, balance training and coordination)
Number of subjects: 30
Study: 16172624

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (4 x 5 g of creatine monohydrate daily for 6 days)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (maltodextrin, daily for 6 days)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 14520721

Group type: EXPERIMENTAL
Intervention: Long-acting β2-adrenoceptor agonists (LABAs)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Long-acting β2-adrenoceptor agonists (LABAs) with regular maintenance with inhaled corticosteroids (ICS)
Number of subjects: 8
Study: 10944595

Group type: EXPERIMENTAL
Intervention: Adjuvant CMF chemotherapy (given to 77 patients, 65%)
Number of subjects: 119

Group type: COMPARATOR
Intervention: No chemotherapy (control group)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Adjuvant CMF chemotherapy
Number of subjects: 119
Study: 9291399

Group type: EXPERIMENTAL
Intervention: alfusozine
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: carbachol/diazepam
Number of subjects: 249

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 249
Study: 8349935

Group type: EXPERIMENTAL
Intervention: Furosemide (20 mg intranasal)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 3091373

Group type: EXPERIMENTAL
Intervention: Erythromycin Brand 1
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Erythromycin Brand 2
Number of subjects: 38

Group type: COMPARATOR
Intervention: Phenoxymethyl-penicillin potassium
Number of subjects: 38
Study: 28822559

Group type: EXPERIMENTAL
Intervention: Postoperative antibiotics (7 days of oral metronidazole and ciprofloxacin)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Standard care without antibiotics
Number of subjects: 307
Study: 27062352

Group type: COMPARATOR
Intervention: Closed suction drain placement
Number of subjects: 0
Study: 24714011

Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl 25 μg plus 3 ml of 0.5% hyperbaric bupivacaine (Group FB)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Intrathecal tramadol 25 mg plus 3 ml of 0.5% hyperbaric bupivacaine (Group TB)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Normal saline plus 3 ml of 0.5% hyperbaric bupivacaine (Group SB)
Number of subjects: 186
Study: 22992271

Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency tonsillectomy
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Bipolar electrocautery tonsillectomy
Number of subjects: 300

Group type: COMPARATOR
Intervention: Ultrasonic scalpel tonsillectomy
Number of subjects: 300

Group type: COMPARATOR
Intervention: Cold steel dissection tonsillectomy
Number of subjects: 300
Study: 19740393

Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg alone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Imatinib 400 mg with omeprazole 40 mg (administered 15 min before imatinib on day 5)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Imatinib 400 mg with omeprazole 40 mg
Number of subjects: 12
Study: 17711168

Group type: EXPERIMENTAL
Intervention: Systematized care plan
Number of subjects: 256

Group type: COMPARATOR
Intervention: Conventional care plan
Number of subjects: 256
Study: 14692022

Group type: EXPERIMENTAL
Intervention: 4 mg of Zoledronic acid (Zol)
Number of subjects: 1130

Group type: COMPARATOR
Intervention: 90 mg of Pamidronate (Pam)
Number of subjects: 1130
Study: 11207631

Group type: COMPARATOR
Intervention: Testosterone alone (group 1, n = 10)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Testosterone with 10 mg oestradiol (group 2, n = 7)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Testosterone with 20 mg oestradiol (group 3, n = 6)
Number of subjects: 23
Study: 9734787

Group type: EXPERIMENTAL
Intervention: Lay health advisers recommended screening and offered a convenient screening opportunity
Number of subjects: 100
Study: 8037337

Group type: EXPERIMENTAL
Intervention: Pulse-intensive regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard regimen
Number of subjects: 0
Study: 2720925

Group type: EXPERIMENTAL
Intervention: Aspirin plus gamma-globulin, 400 mg/kg/day for 4 consecutive days (n = 28, 60%)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Aspirin alone (n = 19, 40%)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 98
Study: 28945641

Group type: EXPERIMENTAL
Intervention: 4-week finger grip training program (suspensions on small holds, 2 times a week)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Climbing exercises only (control group)
Number of subjects: 14
Study: 28034891

Group type: EXPERIMENTAL
Intervention: Presence of anti-FVIII NNAs
Number of subjects: 237

Group type: COMPARATOR
Intervention: Absence of anti-FVIII NNAs
Number of subjects: 237
Study: 25500348

Group type: EXPERIMENTAL
Intervention: Living with Tics (LWT) intervention
Number of subjects: 24

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 24
Study: 24015263

Group type: EXPERIMENTAL
Intervention: Humanlike face display
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Silver face display
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: No-face display
Number of subjects: 30

Group type: COMPARATOR
Intervention: All robot displays
Number of subjects: 30
Study: 21327798

Group type: EXPERIMENTAL
Intervention: Low-frequency vibration recovery (LFV-rec) - 20 Hz; 4 mm for 15 min after exercise
Number of subjects: 12

Group type: COMPARATOR
Intervention: Passive recovery (P-rec) - sitting without vibration stimulus for 15 min after exercise
Number of subjects: 12